Rallybio Corp
RLYB0.785USD
+0.007+0.93%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
32.92MMarket Cap
LossP/E TTM
More Details of Rallybio Corp Company
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Rallybio Corp Info
Ticker SymbolRLYB
Company nameRallybio Corp
IPO dateJul 29, 2021
CEOUden (Stephen)
Number of employees25
Security typeOrdinary Share
Fiscal year-endJul 29
Address234 Church Street
CityNEW HAVEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06510
Phone12038593820
Websitehttps://rallybio.com/
Ticker SymbolRLYB
IPO dateJul 29, 2021
CEOUden (Stephen)
Company Executives of Rallybio Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Wendy K. Chung, M.D., Ph.D.
Dr. Wendy K. Chung, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.36K
+1.56%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
23.88K
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
14.24K
+184.74%
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
636.00K
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.93%
Johnson & Johnson Innovation-JJDC, Inc.
8.61%
5AM Ventures
8.59%
New Leaf Venture Partners LLC
7.82%
TPG Capital, L.P.
7.17%
Other
57.88%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
9.93%
Johnson & Johnson Innovation-JJDC, Inc.
8.61%
5AM Ventures
8.59%
New Leaf Venture Partners LLC
7.82%
TPG Capital, L.P.
7.17%
Other
57.88%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.70%
Investment Advisor
11.96%
Investment Advisor/Hedge Fund
10.98%
Private Equity
7.17%
Individual Investor
4.10%
Hedge Fund
3.00%
Research Firm
0.14%
Pension Fund
0.03%
Other
28.92%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
138
29.20M
69.11%
-6.14M
2025Q2
146
33.40M
80.25%
-5.22M
2025Q1
153
34.13M
82.02%
-4.90M
2024Q4
156
33.77M
81.40%
-4.07M
2024Q3
163
33.31M
80.30%
-4.27M
2024Q2
165
34.52M
83.29%
-5.35M
2024Q1
149
33.11M
86.93%
-2.72M
2023Q4
143
34.47M
90.96%
-619.59K
2023Q3
138
35.89M
94.72%
-1.76M
2023Q2
134
36.21M
95.77%
-44.55K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
4.19M
10.04%
--
--
Jun 30, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.64M
8.7%
--
--
Jun 30, 2025
5AM Ventures
3.63M
8.69%
--
--
Jun 30, 2025
New Leaf Venture Partners LLC
3.30M
7.9%
--
--
Jun 30, 2025
TPG Capital, L.P.
3.03M
7.25%
--
--
Jun 30, 2025
Pivotal Bioventure Partners Investment Advisor LLC
2.40M
5.75%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
1.87M
4.48%
+85.06K
+4.76%
Jun 30, 2025
Almitas Capital LLC
1.82M
4.35%
+516.91K
+39.74%
Jun 30, 2025
The Vanguard Group, Inc.
909.94K
2.18%
-61.99K
-6.38%
Jun 30, 2025
Aju IB Investment Co., Ltd.
754.68K
1.81%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Rallybio Corp?
The top five shareholders of Rallybio Corp are:
Viking Global Investors LP holds 4.19M shares, accounting for 10.04% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 3.64M shares, accounting for 8.70% of the total shares.
5AM Ventures holds 3.63M shares, accounting for 8.69% of the total shares.
New Leaf Venture Partners LLC holds 3.30M shares, accounting for 7.90% of the total shares.
TPG Capital, L.P. holds 3.03M shares, accounting for 7.25% of the total shares.
Viking Global Investors LP holds 4.19M shares, accounting for 10.04% of the total shares.
Johnson & Johnson Innovation-JJDC, Inc. holds 3.64M shares, accounting for 8.70% of the total shares.
5AM Ventures holds 3.63M shares, accounting for 8.69% of the total shares.
New Leaf Venture Partners LLC holds 3.30M shares, accounting for 7.90% of the total shares.
TPG Capital, L.P. holds 3.03M shares, accounting for 7.25% of the total shares.
What are the top three shareholder types of Rallybio Corp?
The top three shareholder types of Rallybio Corp are:
Viking Global Investors LP
Johnson & Johnson Innovation-JJDC, Inc.
5AM Ventures
Viking Global Investors LP
Johnson & Johnson Innovation-JJDC, Inc.
5AM Ventures
How many institutions hold shares of Rallybio Corp (RLYB)?
As of 2025Q3, 138 institutions hold shares of Rallybio Corp, with a combined market value of approximately 29.20M, accounting for 69.11% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -11.14%.
What is the biggest source of revenue for Rallybio Corp?
In FY2024, the -- business generated the highest revenue for Rallybio Corp, amounting to -- and accounting for --% of total revenue.
